Cadila Healthcare to acquire Claris Lifesciences’ injectables business: Reports

21 May 2015 Evaluate

Cadila Healthcare is reportedly in talks to acquire generic sterile injectables business of Claris Lifesciences (CLL).  Cadila is likely to pay a hefty premium, valuing the company at Rs 3,100-3,400 crore. Both sides are currently engaged in last-minute due diligence negotiations involving tax and other financial matters. 

For 12 months ended December 31, 2014, the injectables business posted revenues of Rs 405.6 crore and EBITDA of Rs 149.4 crore(37% EBITDA margin). Therefore, the business is being valued at over 22 times EV/EBITDA. To put it in perspective, the current market cap of parent CLL, including all the businesses, is Rs 1,793 crore.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. It is the only Indian pharma company to launch its own patented NCE - Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidemia.

Zydus Lifesciences Share Price

925.30 1.60 (0.17%)
11-Dec-2025 12:58 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1797.25
Dr. Reddys Lab 1274.00
Cipla 1508.40
Zydus Lifesciences 925.30
Lupin 2078.10
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×